associated with unfavorable overall survival from starting of secondline CTx (P ¼ 0.013). Multivariate analysis model including all pathological features, part of a tumor, and regimen of second-line therapy showed that TUBB3 expression was identified as an independent predictor (hazard ratio ¼ 5.18, 95% confidential intervals ¼ 1.85 -14.53, P ¼ 0.002).
INTRODUCTION AND OBJECTIVES: Latent recurrences despite favorable pathology has been a longstanding conundrum in surgical oncology. In muscle-invasive urothelial carcinoma of the bladder, patients with clinically localized disease (pT2 N0) have a recurrence rate of 11-35% following radical cystectomy, with recurrence rates in higher stages of localized disease up to 50-69% (pT4 N0). Recurrence with N0 disease may be attributed to lymph node micrometastases, therefore improved pathologic staging of lymph nodes may add precision to selecting adjuvant therapy as well as stratifying patients with metastatic disease. Here, we describe a diagnostic approach combining fluorescence activated cell sorting and next-generation sequencing that identifies micrometastases in a patient with muscle-invasive urothelial carcinoma of the bladder.
METHODS: Tumor specimens from multiple regions of patient's bladder tumor as well as lymph nodes were obtained and were dissociated into a single cell suspension. Fluorescence activated cell sorting using the surface markers CD44 and CD49f was utilized to isolate a cancer cell subpopulation associated with stemness. Wholeexome sequencing and RNA sequencing of total cells and the CD44+CD49f+ subpopulation in multiple tumor specimens and regional lymph nodes were performed in order to identify micrometastases and evaluate gene expression among the different regions and populations.
RESULTS: Pathology of the lymph nodes resected demonstrated N0 disease. Mean allele frequency analysis demonstrated a significant correlation between tumor cancer cells and cancer cells isolated from the lymph nodes. RNA-sequencing revealed intratumoral heterogeneity as well as enrichment for immune system and lipid metabolism gene sets in the micrometastatic cancer cell subpopulations.
CONCLUSIONS: Although pathology demonstrated no lymph node disease, we were able to isolate a cancer cell subpopulation from the pathologically negative lymph nodes. Whole-exome sequencing verified the cells isolated from the lymph nodes were indeed similar to the primary tumor and RNA-seq demonstrated differences in gene expression among the total population and subpopulation. Our analysis illustrates how next-generation sequencing of cancer cell subpopulations can be utilized to improve pathologic staging, and provide insight into cancer stem cell biology. (BC) . Therefore, establishment of more efficient therapeutic strategy is urgently desired. Recently, extracellular exosomes are paid attention as important mediators of intercellular communication. Tumor-derived exosomes have known to transfer proteins and nucleic acids from the cells of origin to target cells and affect tumor progression and metastatic process. We have been reported that signaling adaptor protein CRK promotes cell growth, invasion, and adhesion in various cancers, however; the relationship between CRK and exosomes has remained unknown. Here, we investigated the effects of CRK-mediated exosomes on tumor progression and metastasis of BC.
Source of
METHODS: Human BC cell line UM-UC-3 were stably transfected with pCSII-CMV-tdTomato-Luc, and CRK was knocked-down by shRNA technique. The parental and CRK-depleted cells (CRKi) were orthotopically injected into nude mice, and the tumor progression and metastasis were investigated using IVIS Spectrum. In in vitro setting, expression levels of proteins associated with cell growth, survival, and invasion were examined in parental and CRKi UM-UC-3 cells and their exosomes, and the proteins contained in exosomes were identified by LC-TOF/MS. Low grade BC 5637 cells and HUVECs were treated with exosomes from parental UM-UC-3 cells, and the cell proliferation and invasion were analyzed. Furthermore, the metastases in mice pretreated with exosomes from parental and CRKi cells were investigated.
RESULTS: CRKi UM-UC-3 cells inhibited the tumor progression and metastasis in orthotopic xenograft models. We found that CRK and ErbB2 were contained in exosome from the parental UM-UC-3 cells, and the exosomes-incorporated-5637 and -HUVECs significantly promote the cell proliferation and invasion. In contrast, in exosomes from CRKi cells, the expression levels of ErbB2 were reduced, and the exosome-incorporated recipient cells decreased the growth and invasion. Of note, lung metastasis of UM-UC-3 cells was facilitated in mice educated by the parental UM-UC-3-derived exosomes, but not by CRKi cells-derived exosomes.
CONCLUSIONS: Here, we provide novel findings that CRKregulated up-regulation of ErbB2 in the exosomes of BC facilitated the tumor progression and metastasis. Therefore, CRK and ErbB2 might be potent therapeutic targets to prevent the locally advanced and metastasis for BC patients. INTRODUCTION AND OBJECTIVES: Genome wide profiling studies across cancers have been key to the increased understanding of tumour heterogeneity and recent efforts from large muscle invasive bladder cancer (MIBC) cohorts have led to their classification into molecular subtypes displaying distinct genomic and transcriptomic features. Herein, we performed a comprehensive in silico immune transcriptomic profiling using publicly available datasets to identify Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1175 immune gene expression patterns associated with molecular subtypes of MIBC. METHODS: We utilized the publicly available global transcriptomic sequencing (RNA-Seq) data from 412 MIBC cases, with the corresponding clinical information downloaded from The Cancer Genome Atlas (TCGA) data Portal. Cases were divided into discovery (n¼122) and validation (n¼245) cohorts for downstream analysis and were divided into four clusters based on their genomic profiles. To investigate the presence of subtype associated immune signatures we assembled a defined set of 828 immune related genes, consisting of genes involved primarily in Type I and II interferon pathways in addition to other immune response and immune cell phenotype genes. All downstream data analysis was performed in R Bioconductor statistical environment. A one-way ANOVA was utilized to determine significantly differentially expressed genes with a Benjamini and Hochberg correction for false-discovery rate (FDR) correction of q<0.05.
RESULTS: In the 122 case discovery cohort, we identified a total of 452 genes differentially expressed among the four clusters with an FDR q<0.05. The performance of these differentially expressed genes to accurately distinguish the four TCGA clusters was evaluated by unsupervised clustering of both genes and samples. The 64 top 20% of ranked genes were able to distinguish the four clusters in an unsupervised analysis of both the discovery and validation cohorts. The most enriched biological processes in the 452 gene list were response to IFN-g, antigen processing and presentation, cytokine mediated signalling, cell proliferation, NK cell and macrophage activation and B cell mediated immunity The top five overrepresented pathways included, JAK/STAT signalling pathway, Toll receptor signalling pathway, interleukin signalling pathway, and T cell activation. Kaplan Meier survival analysis revealed that in combination, higher expression of three genes, SA100A7, S100A8 and SERPINB2 significantly associated with decreased survival only between clusters I and III in both discovery and validation cohorts.
CONCLUSIONS: Recent evolving findings from completed immunotherapy based clinical trials have emphasized the value of preexisting tumour immune state that potentially determines response to treatment and survival. Our analyses reveal a grouping of immune gene expression patterns using both supervised and unsupervised clustering approaches. Given that specific genetic alterations associate with these molecular subtypes it seems that anti-tumour immune responses could be partly driven by oncogenic drivers. The findings provide further insights into the association between genomic subtypes and immune activation in MIBC and may open novel opportunities for their exploitation towards precise treatment with immunotherapy.
Source of Funding: none

MP88-06
NUCLEAR FACTOR (NF)-kB SIGNALS PROMOTE UROTHELIAL TUMORIGENESIS THROUGH THE ANDROGEN RECEPTOR (AR) PATHWAY Hiroki Ide*, Tokyo, Japan; Satoshi Inoue, Taichi Mizushima, Rochester, NY; Mototsugu Oya, Tokyo, Japan; George Netto, Birmingham, AL; Hiroshi Miyamoto, Rochester, NY INTRODUCTION AND OBJECTIVES: Emerging preclinical evidence has indicated the involvement of AR signaling in urothelial tumorigenesis. Meanwhile, cross-talk between AR and NF-kB, a protein complex of transcriptional factor and its phosphorylation is required for optimal induction of target genes, has been demonstrated in prostate cancer cells. We therefore investigated the role of NF-kB in neoplastic transformation of urothelial cells in relation to AR signaling.
METHODS: We immunohistochemically stained for NF-kB and phospho-NF-kB (p-NF-kB) in 149 bladder tumor and paired nonneoplastic bladder tissue specimens. Then, in immortalized human normal urothelial SVHUC sublines stably expressing AR with exposure to a chemical carcinogen 3-methylcholanthrene (MCA), we assessed the effects of NF-kB activator (betulinic acid; BA) and inhibitor (parthenolide; PAR) on the expression of AR, NF-kB p65 subunit, oncogenes, and tumor suppressors (via RT-PCR or western blot) as well as neoplastic transformation (via cell viability assay and plate/soft agar colony formation assays). Finally, N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) was given to male C57BL/6 mice to induce bladder tumors.
RESULTS: NF-?B and p-NF-?B were positive in 100% [9% weak (1+), 40% moderate (2+), 51% strong (3+)] and 69% (44% 1+, 24% 2+, 1% 3+) of tumors, which was significantly elevated compared with non-neoplastic urothelial tissues [100% (25% 1+, 40% 2+, 35% 3+), P¼0.016 (0/1+/2+ vs. 3+); and 46% (36% 1+, 10% 2+), p<0.001 (0 vs. 1+/2+/3+)]. Significantly higher rates of p-NF-kB positivity were also seen in high-grade (76%, P¼0.015) or muscle-invasive (78%, P¼0.033) tumors than in low-grade (56%) or non-muscle-invasive (62%) tumors. In SVHUC-AR cells, BA induced and PAR reduced the expression of p65 and AR. Notably, BA accelerated and PAR prevented neoplastic transformation of MCA-SVHUC-AR cells, but not that of MCA-SVHUC cells. Additionally, in MCA-SVHUC-AR cells, BA upregulated the expression of c-myc and down-regulated that of p53, p21, and UGT1A, while PAR showed the opposite results. Moreover, bladder tumors were identified in 56% (mock), 89% (BA), and 22% (PAR) of BBN-treated mice sacrificed at 21 weeks of age.
CONCLUSIONS: Compared with non-neoplastic urothelium, NF-kB appeared to be activated in bladder cancer. In addition, NF-kB modulators were found to involve the regulation of tumorigenesis in ARactivated urothelial cells. Accordingly, NF-kB inhibition, together with AR inactivation, has the potential of being an effective chemopreventive approach for urothelial carcinoma.
